Clinical trials: CYP19
Advanced Breast Cancer
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women with Advanced Breast Cancer A Prospective Trial.
- Trial name
- NCT01311037
- Testing
- GnRh Analogue and Aromatase Inhibitor
- Where
- Saudi Arabia
- Volunteers
- 2 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Breast Cancer, Osteoporosis, Osteopenia
Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor
This study evaluates the efficacy of the probiotic food supplement Vivomixx in the prevention of bone loss occurring in post menopausal women with breast cancer treated with an aromatase inhibitor.
- Trial name
- NCT03518268
- Testing
- Vivomixx
- Volunteers
- 40 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Breast Cancer
Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer
This multicenter, randomized, comparative study will evaluate the efficacy of denosumab to prevent the adjuvant therapy of aromatase inhibitors-induced loss of bone mineral density (BMD) in breast cancer patients with normal BMD.
- Trial name
- NCT03324932
- Testing
- Denosumab Injection
- Where
- Japan
- Volunteers
- 160 people
- Sponsor
- Kyoto Prefectural University of Medicine
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors
This phase IV trial studies whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors (BCS) who are taking an aromatase inhibitor.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT07769047
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry, Functional Assessment
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Metastatic Breast Cancer
A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
The reason for this study is to see if the drug abemaciclib in combination with nonsteroidal aromatase inhibitors (anastrozole or letrozole) is effective in participants with Hormone Receptor Positive (HR+), Human Epidermal…
- Trial name
- proMONARCH (NCT03988114)
- Testing
- Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI)
- Where
- 119 sites in United States, Argentina and 7 more
- Sponsor
- Eli Lilly and Company
Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
Both Tart Cherry and Omega 3 FAs have better side effect profiles compared to other commonly used medications for AIMSS, such as nonsteroidal anti-inflammatories, steroids, and serotonin norepinephrine reuptake inhibitors.
- Conditions
- Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
- Trial name
- NCT06123286
- Testing
- Tart Cherry, Omega 3 FA (Fish Oil)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Philip Chang
Pregnancy, Unexplained Infertility
Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation
The objective of this application is to identify a pharmacologic agent which helps couples in whom the female partner ovulates regularly successfully obtain their goal of delivering a healthy child, whose use will result in low…
- Trial name
- AMIGOS (NCT01044862)
- Testing
- Letrozole (aromatase inhibitor), Clomiphene Citrate, Follicle Stimulating Hormone (gonadotropin)
- Where
- 14 sites in United States
- Volunteers
- 900 people
- Sponsor
- Yale University
Breast Cancer, Other Disorders of Bone Density and Structure
Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer
The purpose of this study is to identify the combined impact on bone loss as well as the incidence of bone fractures in women with estrogen receptor (ER)-positive, early breast cancer treated with an aromatase inhibitor (AI)…
- Trial name
- POCHARBI (NCT01298362)
- Testing
- Aromatase Inhibitors, Chemotherapy
- Where
- Greece
- Volunteers
- 290 people
- Sponsor
- Hellenic Breast Surgeons Society
Low Serum Testosterone Levels in Man
D-chiro-inositol Increases Androgens and Reduces Estrogens in Human Serum
The aim of this pilot study is to test the effect of a 30 day-D-chiro-inositol oral treatment on a set of clinical parameters (mainly sex hormones) in a group of male volunteers selected by their age and BMI to investigate if…
- Trial name
- NCT04615767
- Testing
- D-chiro-inositol
- Where
- Italy
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AGUNCO Obstetrics and Gynecology Centre
Metastatic Breast Cancer
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
This is an international (4 countries) randomized phase III study with 2 cohorts, patients will be randomized 1:1 to endocrine therapy (cohort 1: exemestane 25 mg daily, cohort 2: fulvestrant 500mg days 1 and 15 cycle 1 and then…
- Trial name
- PEARL (NCT02028507)
- Testing
- Palbociclib, Capecitabine, Exemestane
- Where
- 37 sites in Austria, Hungary and 2 more
- Volunteers
- 693 people
- Sponsor
- Spanish Breast Cancer Research Group
Arthralgia, Breast Cancer
Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
Study of Cannabidol to examine the safety and efficacy of 15 weeks of CBD in postmenopausal women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
- Trial name
- NCT04754399
- Testing
- Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Cancer
A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
This international, multicenter, randomized, double-blinded, placebo-controlled study is designed to compare the efficacy and safety of taselisib + fulvestrant with that of placebo + fulvestrant in postmenopausal women with…
- Trial name
- SANDPIPER (NCT02340221)
- Testing
- Taselisib, Fulvestrant
- Where
- 157 sites in United States, Australia and 26 more
- Volunteers
- 631 people
- Sponsor
- Hoffmann-La Roche
Aromatase Inhibitor, Musculoskeletal Symptoms
Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings
Aromatase inhibitor therapy has become a standard adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer.
- Conditions
- Aromatase Inhibitor, Musculoskeletal Symptoms, Postmenopausal Breast Cancer Survivors
- Trial name
- NCT03697200
- Testing
- APA, Education control
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Johns Hopkins University
Breast Cancer
Coagulation Parameters in Postmenopausal Breast Cancer Patients Under Adjuvant Hormonal Therapy
The objective of the study is to monitor the changes of blood coagulation parameters in postmenopausal patients who are treated with adjuvant Hormonal Therapy for a total of 5 years.
- Trial name
- COPA (NCT00814034)
- Where
- 2 sites in Greece
- Volunteers
- 306 people
- Sponsor
- Hellenic Breast Surgeons Society
Musculoskeletal Symptoms, Breast Cancer
Evaluating the Efficacy of Structured Exercise Interventions in Alleviating Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors: a Pilot Study Protocol
Endocrine therapy represents a foundational approach for managing hormone receptor-positive breast cancer, with treatment typically spanning 5 to 10 years.
- Conditions
- Musculoskeletal Symptoms, Breast Cancer, Endocrine Therapy, Aromatase Inhibitors
- Trial name
- RE-MS (NCT06754293)
- Testing
- rehabilitation exercise
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Fudan University
Symptomatic or Large Uterine Fibroids
Aromatase Inhibitors for Treatment of Uterine Leiomyomas
Fibroids are benign tumors that might results in bleeding. Surgery is their definitive treatment. Some medical therapies have been tried for women who wish to preserve their uterus.
- Trial name
- NCT00945360
- Testing
- Letrozole (aromatase inhibitor)
- Where
- Lebanon
- Sponsor
- American University of Beirut Medical Center
Sexuality
Breast Cancer, Sexuality and Black Cohosh
The purpose of this study is to evaluate the Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen or aromatase inhibitor through questionnaires.
- Trial name
- Cimicifuga (NCT02467686)
- Testing
- WHOQOL questionnaire, FSFI questionnaire, kupperman scale
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Irmandade da Santa Casa de Misericordia de Sao Paulo
Mammographic Density
Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density
To evaluate the impact of a selective androgen receptor modulator combined with an aromatase inhibitor in reducing high mammographic breast density.
- Trial name
- NCT03264651
- Testing
- enobosarm
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- Havah Therapeutics Pty Ltd
Breast Cancer
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, methotrexate, and prednisolone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00687648
- Testing
- anastrozole, cyclophosphamide, exemestane
- Where
- Singapore
- Volunteers
- 70 people
- Sponsor
- National Cancer Centre, Singapore
Breast Cancer
The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer
This study explores how aromatase inhibitor therapy affects risk factors for heart disease in postmenopausal women with breast cancer.
- Trial name
- Silhouette (NCT01080170)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh